Dianthus Therapeutics, Inc./$DNTH

1D1W1MYTD1Y5YMAX

About Dianthus Therapeutics, Inc.

Dianthus Therapeutics Inc. is a clinical-stage biotechnology company dedicated to developing potentially best-in-class therapies for patients with severe autoimmune diseases. The company operates as a single segment and has one reportable segment, focusing on creating next-generation treatments to revolutionize the management of severe autoimmune conditions. The team comprises experienced biotech and pharma executives. The pipeline includes the potential of Claseprubart, a next-generation complement therapeutic.
Ticker
$DNTH
Sector
Health
Primary listing
NASDAQ
Employees
92
Headquarters
New York, United States
Website
dianthustx.com

DNTH Metrics

BasicAdvanced
$4.9B
-
-$4.11
0.08
-

What the Analysts think about DNTH

Analyst ratings (Buy, Hold, Sell) for Dianthus Therapeutics, Inc. stock.
Analyst projections of the future price of Dianthus Therapeutics, Inc. stock.

Bulls say / Bears say

Claseprubart produced a 75% response rate among the first 40 patients completing Part A of the Phase 3 CAPTIVATE CIDP trial, above Dianthus’s 50% go threshold. The company has already advanced to Part B, creating a near-term clinical catalyst. (Dianthus Therapeutics, GlobeNewswire)
Dianthus has started the Phase 3 EMERGE trial in generalised myasthenia gravis after positive Phase 2 results, testing convenient subcutaneous dosing every two or four weeks. FDA Orphan Drug Designation adds regulatory support, while the readout is expected in the second half of 2028. (Dianthus Therapeutics, Dianthus Therapeutics)
The company had about $1.2 billion of cash and investments at 30 June 2026 and expects this to fund operations into 2030. That gives Dianthus room to run the MMN Phase 2 readout, progress DNTH212 and develop DNTH312 without an immediate financing constraint. (Dianthus Therapeutics, Dianthus Therapeutics)
The 75% CIDP figure comes from a small, open-label interim group and may not translate into the randomised Part B result. Dianthus itself flags that interim data may not predict the outcome of the remaining trial, leaving the lead programme exposed to a pivotal-stage setback. (Dianthus Therapeutics, Dianthus Therapeutics)
Dianthus remains loss-making as development spending accelerates: its second-quarter 2026 net loss was $50.2 million and research spending rose to $48.7 million. Although cash is strong, the new $500 million at-the-market share programme creates a clear risk of dilution if the company uses it to fund expansion. (Dianthus Therapeutics, SEC filing report)
The assets outside claseprubart are still early and unproven in people: DNTH212 is in a Phase 1 healthy-volunteer study, while DNTH312 is only intended to become Phase 1-ready by the end of 2027. These programmes provide optionality, but they do not yet reduce the company’s dependence on claseprubart’s clinical success. (Dianthus Therapeutics, BioSpace)
Data summarised monthly by Lightyear AI. Last updated on 23 Sept 2026.

DNTH Financial Performance

Revenues and expenses
Income statement
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
Net income
Profit margin

DNTH Earnings Performance

Company profitability
Earnings per share
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
Expected
Surprise

Funds containing DNTH

AllUSDEURGBP
Funds
Fund name
Fund size
$DNTH weighting
iShares Healthcare Innovation$HEAL
$1.4B0.49%
iShares Healthcare Innovation€2B78
€1.2B0.49%
iShares Healthcare Innovation£DRDR
£1B0.49%
iShares Ageing Population€AGED
€822M0.42%
SPDR Russell 2000 US Small Cap€R2US
€4.8B0.14%
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.